Showing results (41-50 of 79) with videos related to
Sort By:
Pageof 8
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKRyohei Katayama, Tahsin M Khan, Cyril Benes, et al.Frontiers in Cell and Developmental Biology|February 4, 2022
Meclozine Attenuates the MARK Pathway in Mammalian Chondrocytes and Ameliorates FGF2-Induced Bone Hyperossification in Larval ZebrafishGenta Takemoto, Masaki Matsushita, Takaaki Okamoto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 16, 2014
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutationJunya Nakade, Shinji Takeuchi, Takayuki Nakagawa, et al.Cancer Science|April 12, 2025
First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1-Year Follow-Up of the FIRST-Dx StudyJunichi Matsubara, Kumi Mukai, Tomohiro Kondo, et al.JAMA Network Open|July 17, 2023
First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy OpportunitiesJunichi Matsubara, Kumi Mukai, Tomohiro Kondo, et al.Cancer Research|May 4, 2012
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and METLu Xu, Eiki Kikuchi, Chunxiao Xu, et al.Proceedings of the National Academy of Sciences of the United States of America|December 12, 2013
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1Hiromichi Ebi, Carlotta Costa, Anthony C Faber, et al.Plos One|May 22, 2013
mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGFDaisuke Ishikawa, Shinji Takeuchi, Takayuki Nakagawa, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumorsTomohide Tamura, Hironobu Minami, Yasuhide Yamada, et al.The Journal of Clinical Investigation|October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersHiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.Pageof 8